The elucidation of detailed molecules in the acetylation/deacetylation pathway, the discovery of new HAT/HDAC targeted compounds, and the combination of HAT/HDAC inhibitors with other drugs, such as immune checkpoint inhibitors, can all contribute to the finding of new targets and ideas for future cancer immunotherapy. Here, HDAC9 is linked to cancer.